Open AccessAutologous peripheral blood stem cell mobilization following dose‐adjusted cyclophosphamide, doxorubicin, vincristine, and prednisolone chemotherapy alone or in combination with rituximab in treating high‐risk non‐Hodgkin's lymphoma
Author(s) -
Shi Yuankai,
Zhou Ping,
Han Xiaohong,
He Xiaohui,
Zhou Shengyu,
Liu Peng,
Yang Jianliang,
Zhang Changgong,
Gui Lin,
Qin Yan,
Yang Sheng,
Zhao Liya,
Yao Jiarui,
Zhang Shuxiang
Publication year - 2015
Publication title -
cancer communications
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.119
H-Index - 53
ISSN - 2523-3548
DOI - 10.1186/s40880-015-0045-3
Subject(s) - chop , medicine , rituximab , vincristine , lymphoma , prednisolone , gastroenterology , autologous stem cell transplantation , cyclophosphamide , chemotherapy , non hodgkin's lymphoma , urology , oncology , surgery
Background The regimen of cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) is an efficient treatment of non‐Hodgkin's lymphoma (NHL). This study aimed to assess the efficacy and toxicity of dose‐adjusted CHOP alone or in combination with rituximab (R‐CHOP) by examining the stem cell mobilization in NHL patients. Factors affecting the collection of CD34 + cells were also explored. Methods Our retrospective study included 39 patients eligible for autologous stem cell transplantation: 14 patients who expressed CD20 and were financially eligible received R‐CHOP for autologous peripheral blood stem cell (APBSC) mobilization; the remaining 25 patients received CHOP. Results The median CD34 + cell yield was 7.01 × 10 6 cells/kg body weight (range 1.49–28.39 × 10 6 cells/kg body weight), with only two patients failing to meet the target CD34 + cell harvest of ≥2.0 × 10 6 cells/kg body weight. The median number of apheresis procedures per patient was 1 (range 1–3). The APBSC mobilization yield of the CHOP group appeared to be higher than that of the R‐CHOP group ( P = 0.005), whereas the success rate was similar between groups. R‐CHOP elevated the complete response (CR) rate in B cell lymphoma patients as compared with CHOP ( P = 0.01). No significant differences in toxicity or engraftment were observed between the two groups. Conclusion The present study demonstrated that dose‐adjusted CHOP chemotherapy effectively mobilized APBSCs in NHL patients and that the addition of rituximab to dose‐adjusted CHOP chemotherapy elevated the CR rate for patients with B‐cell lymphoma.